The development of a novel digital PCR assay in collaboration with the FBI positions Qiagen at the forefront of forensic science technology. This partnership not only enhances Qiagen's product portfolio but also its reputation in the forensic and diagnostics markets. The unique capabilities of the assay, such as quantifying minimal DNA amounts and assessing sample quality, address critical challenges in forensic analysis, potentially leading to increased demand for Qiagen's QIAcuity devices. Given the specificity of the technology and its application in a high-stakes field like forensics, this collaboration is likely to have a positive short-term impact on Qiagen's stock as it highlights the company's innovation and expands its market reach.